Search
Jefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy
CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal. Coverage brought to you by
Nov 18
Paris based Nanobiotix has always had a nanophysics approach to medicine - the ways they are applying it could be expanding soon
Founder and CEO Laurent Levy gives an update on the company's robust radiation oncology program, and describes two new areas of...
Sep 4, 2024
Analyzing Nanobiotix's P1 Head & Neck data for the radioenhancer NBTXR3 from #ASTRO2023
CEO Laurent Levy walks us through the data and makes his argument that patients' OS was greater than what would be expected.
Oct 10, 2023
Nanobiotix's CEO explains how his company is trying to boost the efficacy of radiation therapy
Laurent Levy talks about his company’s nanoparticle technology, a recent deal with Janssen, and the state of European biotech.
Jul 27, 2023
.png){kind=logo}
